Testing ravulizumab for neuromyelitis optica
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests if ravulizumab can lower certain nerve damage markers in people with AQP4-positive neuromyelitis optica. It may help understand how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with AQP4-positive neuromyelitis optica (NMOSD) using standard criteria.
- You have had at least one flare-up or attack of NMOSD before.
- You either have not been treated for NMOSD before, or have taken specific medications like rituximab, steroids, azathioprine, mycophenolate mofetil, or ravulizumab. If you are new to ravulizumab, you must have a prescription for it but not started it yet.
- You have been vaccinated against N. meningitidis (meningitis) within the last 3 years, or you will get the vaccine when you start the study, with antibiotics as a safety measure.
- You weigh at least 40 kg (about 88 pounds).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called ravulizumab (an infusion) to reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition affecting the optic nerve and spinal cord. The trial is specifically enrolling adults in China who have had recent disease activity.
This trial tests an antibody treatment for people having a neuromyelitis optica (NMO) relapse. It may reduce nerve damage from inflammation during an acute attack.
This trial compares several medications to see which works best for NMOSD, an autoimmune disease that can cause vision loss and paralysis. You must have a specific antibody (AQP4-IgG) to join.
This trial studies satralizumab in children ages 2 to 11 with a specific type of NMOSD caused by AQP4 antibodies. It aims to see how well the medicine prevents attacks and is safe over time.
This registry collects health and relapse information from adults with AQP4-positive NMOSD who are taking C5-blocking medicines to prevent long-term relapses. It helps researchers better understand treatment patterns and outcomes in real-world care.
This study follows people with NMOSD (a rare autoimmune disease that can cause vision loss and paralysis) to learn more about the condition. It may help doctors better understand and treat NMOSD in the future.
Hear when a new NMOSD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.